CD79A and COVID-19: However, based on the findings of this paper, it is speculated that the activation of humoral immune responses and the resultant development of IgG1, IgM, and IgA antibodies to auto‐antigens in GD patients act as a strong marketer for continuous development of IgG1, IgM, and IgA antibodies to different structural proteins, (e.g. S, RBD of S and N) of SARS‐CoV2 in GD patients with COVID‐19.